Bovine lactoferrin improves bone status of ovariectomized mice via immune function modulation

Bone

Volumn 48, Issue 5, 2011, Pages 1028-1035

  Malet, Arnaud ^a,b   Bournaud, Elsa ^a   Lan, Annaïg ^a   Mikogami, Takashi ^b   Tomé, Daniel ^a   Blais, Anne ^a  

^a INRA Institut National de la Recherche Agronomique   (France)

^b Armor Protéines ^*  (France)

Author keywords

Bone resorption; Immunomodulation; Lactoferrin; Osteoclastogenesis

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; ESTROGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 6; LACTOFERRIN; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE DENSITY; BONE MARROW; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DIET SUPPLEMENTATION; ESTROGEN DEFICIENCY; FEMALE; FLOW CYTOMETRY; IMMUNOMODULATION; LEUKOCYTE; MACROPHAGE; MOUSE; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE MARROW CELLS; CATTLE; CELL DIFFERENTIATION; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; LACTOFERRIN; LEUKOCYTES; LYMPHOCYTE ACTIVATION; MICE; OSTEOCLASTS; OSTEOGENESIS; OVARIECTOMY; RANK LIGAND; RNA, MESSENGER; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79954614799     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.02.002     Document Type: Article

References (65)

1. Omi N., Ezawa I. The effect of ovariectomy on bone metabolism in rats. Bone 1995, 17:163S-168S.
2. De Laet C.E., van Hout B.A., Burger H., Hofman A., Pols H.A. Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 1997, 315:221-225.
3. Pfeilschifter J., Koditz R., Pfohl M., Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002, 23:90-119.
4. Cornish J., Palmano K., Callon K.E., Watson M., Lin J.M., Valenti P., et al. Lactoferrin and bone; structure-activity relationships. Biochem Cell Biol 2006, 84:297-302.
5. Blais A., Malet A., Mikogami T., Martin-Rouas C., Tome D. Oral bovine lactoferrin improves bone status of ovariectomized mice. Am J Physiol Endocrinol Metab 2009, 296:E1281-E1288.
6. Lorget F., Clough J., Oliveira M., Daury M.C., Sabokbar A., Offord E. Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. Biochem Biophys Res Commun 2002, 296:261-266.
7. Guo H.Y., Jiang L., Ibrahim S.A., Zhang L., Zhang H., Zhang M., et al. Orally administered lactoferrin preserves bone mass and microarchitecture in ovariectomized rats. J Nutr 2009, 139:958-964.
8. Legrand D., Elass E., Carpentier M., Mazurier J. Interactions of lactoferrin with cells involved in immune function. Biochem Cell Biol 2006, 84:282-290.
9. Debbabi H., Dubarry M., Rautureau M., Tome D. Bovine lactoferrin induces both mucosal and systemic immune response in mice. J Dairy Res 1998, 65:283-293.
10. Wakabayashi H., Takakura N., Yamauchi K., Tamura Y. Modulation of immunity-related gene expression in small intestines of mice by oral administration of lactoferrin. Clin Vaccine Immunol 2006, 13:239-245.
11. Yamauchi K., Wakabayashi H., Shin K., Takase M. Bovine lactoferrin: benefits and mechanism of action against infections. Biochem Cell Biol 2006, 84:291-296.
12. Bouxsein M.L., Myers K.S., Shultz K.L., Donahue L.R., Rosen C.J., Beamer W.G. Ovariectomy-induced bone loss varies among inbred strains of mice. J Bone Miner Res 2005, 20:1085-1092.
13. Cenci S., Weitzmann M.N., Roggia C., Namba N., Novack D., Woodring J., et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000, 106:1229-1237.
14. Srivastava S., Toraldo G., Weitzmann M.N., Cenci S., Ross F.P., Pacifici R. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem 2001, 276:8836-8840.
15. Weitzmann M.N., Pacifici R. The role of T lymphocytes in bone metabolism. Immunol Rev 2005, 208:154-168.
16. Grassi F., Tell G., Robbie-Ryan M., Gao Y., Terauchi M., Yang X., et al. Oxidative stress causes bone loss in estrogen-deficient mice through enhanced bone marrow dendritic cell activation. Proc Natl Acad Sci USA 2007, 104:15087-15092.
17. Cenci S., Toraldo G., Weitzmann M.N., Roggia C., Gao Y., Qian W.P., et al. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA 2003, 100:10405-10410.
18. Shortman K., Liu Y.J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002, 2:151-161.
19. Diao J., Winter E., Chen W., Cantin C., Cattral M.S. Characterization of distinct conventional and plasmacytoid dendritic cell-committed precursors in murine bone marrow. J Immunol 2004, 173:1826-1833.
20. Alnaeeli M., Teng Y.T. Dendritic cells differentiate into osteoclasts in bone marrow microenvironment in vivo. Blood 2009, 113:264-265. [author reply 265].
21. Alnaeeli M., Park J., Mahamed D., Penninger J.M., Teng Y.T. Dendritic cells at the osteo-immune interface: implications for inflammation-induced bone loss. J Bone Miner Res 2007, 22:775-780.
22. Pacifici R. Estrogen deficiency, T cells and bone loss. Cell Immunol 2008, 252:68-80.
23. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
24. Roggia C., Gao Y., Cenci S., Weitzmann M.N., Toraldo G., Isaia G., et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 2001, 98:13960-13965.
25. Wu J., Wang X.X., Takasaki M., Ohta A., Higuchi M., Ishimi Y. Cooperative effects of exercise training and genistein administration on bone mass in ovariectomized mice. J Bone Miner Res 2001, 16:1829-1836.
26. Fujioka M., Uehara M., Wu J., Adlercreutz H., Suzuki K., Kanazawa K., et al. Equol, a metabolite of daidzein, inhibits bone loss in ovariectomized mice. J Nutr 2004, 134:2623-2627.
27. Price C., Herman B.C., Lufkin T., Goldman H.M., Jepsen K.J. Genetic variation in bone growth patterns defines adult mouse bone fragility. J Bone Miner Res 2005, 20:1983-1991.
28. Legrand D, Mazurier J. A critical review of the roles of host lactoferrin in immunity. Biometals 2010;23:365-76.
29. Schroeder T.M., Jensen E.D., Westendorf J.J. Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res C Embryo Today 2005, 75:213-225.
30. Marie P.J. Transcription factors controlling osteoblastogenesis. Arch Biochem Biophys 2008, 473:98-105.
31. Pacifici R. The immune system and bone. Arch Biochem Biophys 2010;503:41-53.
32. Khosla S., Melton L.J., Riggs B.L. Estrogens and bone health in men. Calcif Tissue Int 2001, 69:189-192.
33. Weitzmann M.N., Pacifici R. Estrogen regulation of immune cell bone interactions. Ann NY Acad Sci 2006, 1068:256-274.
34. Pacifici R. T cells: critical bone regulators in health and disease. Bone 2010;47:461-71.
35. Kimble R.B., Bain S., Pacifici R. The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J Bone Miner Res 1997, 12:935-941.
36. Srivastava S., Weitzmann M.N., Cenci S., Ross F.P., Adler S., Pacifici R. Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. J Clin Invest 1999, 104:503-513.
37. Gao Y., Grassi F., Ryan M.R., Terauchi M., Page K., Yang X., et al. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 2007, 117:122-132.
38. Horowitz M.C., Bothwell A.L., Hesslein D.G., Pflugh D.L., Schatz D.G. B cells and osteoblast and osteoclast development. Immunol Rev 2005, 208:141-153.
39. Miyaura C., Onoe Y., Inada M., Maki K., Ikuta K., Ito M., et al. Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency. Proc Natl Acad Sci USA 1997, 94:9360-9365.
40. Masuzawa T., Miyaura C., Onoe Y., Kusano K., Ohta H., Nozawa S., et al. Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. J Clin Invest 1994, 94:1090-1097.
41. Manabe N., Kawaguchi H., Chikuda H., Miyaura C., Inada M., Nagai R., et al. Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol 2001, 167:2625-2631.
42. Ryan M.R., Shepherd R., Leavey J.K., Gao Y., Grassi F., Schnell F.J., et al. An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc Natl Acad Sci USA 2005, 102:16735-16740.
43. Nalbandian G., Paharkova-Vatchkova V., Mao A., Nale S., Kovats S. The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation. J Immunol 2005, 175:2666-2675.
44. Savina A., Amigorena S. Phagocytosis and antigen presentation in dendritic cells. Immunol Rev 2007, 219:143-156.
45. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997, 272:25190-25194.
46. Yun T.J., Chaudhary P.M., Shu G.L., Frazer J.K., Ewings M.K., Schwartz S.M., et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 1998, 161:6113-6121.
47. Clowes J.A., Riggs B.L., Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 2005, 208:207-227.
48. Blanco P., Palucka A.K., Pascual V., Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 2008, 19:41-52.
49. Rovere P., Sabbadini M.G., Fazzini F., Bondanza A., Zimmermann V.S., Rugarli C., et al. Remnants of suicidal cells fostering systemic autoaggression. Apoptosis in the origin and maintenance of autoimmunity. Arthritis Rheum 2000, 43:1663-1672.
50. Caetano-Lopes J., Canhao H., Fonseca J.E. Osteoimmunology-the hidden immune regulation of bone. Autoimmun Rev 2009, 8:250-255.
51. Cumberbatch M., Dearman R.J., Uribe-Luna S., Headon D.R., Ward P.P., Conneely O.M., et al. Regulation of epidermal Langerhans cell migration by lactoferrin. Immunology 2000, 100:21-28.
52. Legrand D., Pierce A., Elass E., Carpentier M., Mariller C., Mazurier J. Lactoferrin structure and functions. Adv Exp Med Biol 2008, 606:163-194.
53. Puddu P., Valenti P., Gessani S. Immunomodulatory effects of lactoferrin on antigen presenting cells. Biochimie 2009, 91:11-18.
54. Yee C.S., Yao Y., Xu Q., McCarthy B., Sun-Lin D., Tone M., et al. Enhanced production of IL-10 by dendritic cells deficient in CIITA. J Immunol 2005, 174:1222-1229.
55. Mohamed S.G., Sugiyama E., Shinoda K., Taki H., Hounoki H., Abdel-Aziz H.O., et al. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Bone 2007, 41:592-602.
56. Carmody E.E., Schwarz E.M., Puzas J.E., Rosier R.N., O'Keefe R.J. Viral interleukin-10 gene inhibition of inflammation, osteoclastogenesis, and bone resorption in response to titanium particles. Arthritis Rheum 2002, 46:1298-1308.
57. Battaglia M., Gianfrani C., Gregori S., Roncarolo M.G. IL-10-producing T regulatory type 1 cells and oral tolerance. Ann NY Acad Sci 2004, 1029:142-153.
58. Takakura N., Wakabayashi H., Yamauchi K., Takase M. Influences of orally administered lactoferrin on IFN-gamma and IL-10 production by intestinal intraepithelial lymphocytes and mesenteric lymph-node cells. Biochem Cell Biol 2006, 84:363-368.
59. Baveye S., Elass E., Mazurier J., Legrand D. Lactoferrin inhibits the binding of lipopolysaccharides to l-selectin and subsequent production of reactive oxygen species by neutrophils. FEBS Lett 2000, 469:5-8.
60. Legrand D., Elass E., Pierce A., Mazurier J. Lactoferrin and host defence: an overview of its immuno-modulating and anti-inflammatory properties. Biometals 2004, 17:225-229.
61. Legrand D., Elass E., Carpentier M., Mazurier J. Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci 2005, 62:2549-2559.
62. Baker E.N., Baker H.M. Molecular structure, binding properties and dynamics of lactoferrin. Cell Mol Life Sci 2005, 62:2531-2539.
63. Yamauchi K., Wakabayashi H., Hashimoto S., Teraguchi S., Hayasawa H., Tomita M. Effects of orally administered bovine lactoferrin on the immune system of healthy volunteers. Adv Exp Med Biol 1998, 443:261-265.
64. Alnaeeli M., Penninger J.M., Teng Y.T. Immune interactions with CD4+ T cells promote the development of functional osteoclasts from murine CD11c+ dendritic cells. J Immunol 2006, 177:3314-3326.
65. Rivollier A., Mazzorana M., Tebib J., Piperno M., Aitsiselmi T., Rabourdin-Combe C., et al. Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 2004, 104:4029-4037.